SCHEMBL23486417

SCHEMBL23486417

O=C(O)c1nnccc1Nc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FABP4 P15090 1/20 0.46
▸ MAPT P10636 3/20 0.44
▸ GFER P55789 1/20 0.44
▸ NGLY1 Q96IV0 1/20 0.44
▸ DHODH Q02127 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ ALOX15 P16050 2/20 0.40
▸ AKR1C3 P42330 2/20 0.40
▸ AKR1C2 P52895 2/20 0.40
▸ ILK Q13418 1/20 0.40
▸ HCAR3 P49019 2/20 0.39
▸ CASP3 P42574 1/20 0.39
▸ SENP7 Q9BQF6 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22609254 0.85 DHODH (0.46) MAPTDHODHALDH1A1HTTPIM1
SCHEMBL29552554 0.82 HTR2C (0.40) MAPTALDH1A1KDM4EMAPK1
SCHEMBL23486570 0.79 ILK (0.57) MAPTDHODHALDH1A1HPGDHSD17B10
SCHEMBL11136818 0.78 FABP4 (0.45) FABP4MAPTGFERNGLY1DHODH
SCHEMBL3525990 0.77 DHODH (0.56) FABP4MAPTGFERNGLY1DHODH
SCHEMBL28369905 0.74 HSD17B10 (0.42) MAPTDHODHALDH1A1KDM4EHPGD
SCHEMBL4907684 0.71 GRM5 (0.49) FABP4MAPTGFERNGLY1ALDH1A1
SCHEMBL11822171 0.70 KDM4E (0.43) MAPTALDH1A1KDM4EHSD17B10GAA
SCHEMBL28567393 0.69 KDM4E (0.44) MAPTALDH1A1KDM4EALOX15TSHR
SCHEMBL10917448 0.69 FABP4 (0.46) FABP4MAPTGFERNGLY1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF PNPO, XDH, GLS FABP4 4410/4885MAPT 2376/4885GFER 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback